{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-109821","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.518481+00:00","generated_at":"2026-05-16T22:03:37.806873+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Theriva Biologics Q3 2025 cash $7.5M; raises $8M post-quarter, extends runway into Q1 2027","bullets":["Cash and equivalents $7.5M at Sep 30; subsequent raises bring to $15.5M at Nov 10, funding ops into Q1 2027.","Q3 R&D expense $2.6M (-7% YoY); G&A $1.9M (-18% YoY); workforce reduction implemented Sep 30.","VIRAGE Phase 2b data for VCN-01 in metastatic PDAC presented at ESMO; planning Phase 3 discussions with EMA/FDA.","Preclinical data for next-gen oncolytic virus VCN-12 showed improved cell killing and anti-tumor immunity vs VCN-01.","Retinoblastoma Phase 2/3 trial design in progress; regulatory discussion expected H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-109821","json":"https://secwatch.observer/filing/0001104659-25-109821.json","markdown":"https://secwatch.observer/filing/0001104659-25-109821.md","text":"https://secwatch.observer/filing/0001104659-25-109821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465925109821/0001104659-25-109821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465925109821/tm2530928d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:03:37.806873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}